These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 35999119)

  • 41. A clinical trial of neoadjuvant hyperthermic intravesical chemotherapy (HIVEC) for treating intermediate and high-risk non-muscle invasive bladder cancer.
    Sousa A; Inman BA; Piñeiro I; Monserrat V; Pérez A; Aparici V; Gómez I; Neira P; Uribarri C
    Int J Hyperthermia; 2014 May; 30(3):166-70. PubMed ID: 24697672
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Intravesical Bacillus Calmette-Guérin Versus Combination of Epirubicin and Interferon-α2a in Reducing Recurrence of Non-Muscle-invasive Bladder Carcinoma: FinnBladder-6 Study.
    Marttila T; Järvinen R; Liukkonen T; Rintala E; Boström P; Seppänen M; Tammela T; Hellström P; Aaltomaa S; Leskinen M; Raitanen M; Kaasinen E;
    Eur Urol; 2016 Aug; 70(2):341-7. PubMed ID: 27085624
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Intravesical thermochemotherapy in the treatment of high-risk and very high-risk non-muscle-invasive urothelial bladder cancer: a single-arm study.
    Brisuda A; Horňák J; Žemličková B; Háček J; Babjuk M
    Int Urol Nephrol; 2024 Jul; 56(7):2243-2250. PubMed ID: 38329573
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Guidance of adjuvant instillation in intermediate-risk non-muscle invasive bladder cancer by drug screens in patient derived organoids: a single center, open-label, phase II trial.
    Seiler R; Egger M; De Menna M; Wehrli S; Minoli M; Radić M; Lyatoshinsky P; Hösli R; Blarer J; Abt D; Kruithof-de Julio M
    BMC Urol; 2023 May; 23(1):89. PubMed ID: 37170307
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Intravesical radiofrequency-induced hyperthermia combined with chemotherapy for non-muscle-invasive bladder cancer.
    van Valenberg H; Colombo R; Witjes F
    Int J Hyperthermia; 2016 Jun; 32(4):351-62. PubMed ID: 26905963
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Evaluation of the efficacy and safety of HIVEC intravesical thermochemotherapy with intermediate-risk and high-risk non-muscle-invasive bladder cancer].
    Cimier A; Thach S; Lacroix B; Mariat C
    Prog Urol; 2023 Apr; 33(5):254-264. PubMed ID: 36906430
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Sequential intravesical gemcitabine and docetaxel for treatment-naïve and previously treated intermediate-risk nonmuscle invasive bladder cancer.
    McElree IM; Orzel J; Stubbee R; Steinberg RL; Mott SL; O'Donnell MA; Packiam VT
    Urol Oncol; 2023 Dec; 41(12):485.e1-485.e7. PubMed ID: 37442741
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Efficacy of hyperthermic intravesical chemotherapy (HIVEC) in patients with non-muscle invasive bladder cancer after BCG failure.
    Pignot G; Baboudjian M; Lebacle C; Chamouni A; Lechevallier E; Irani J; Tillou X; Waeckel T; Monges A; Doisy L; Walz J; Gravis G; Mourey E; Duperron C; Masson-Lecomte A
    World J Urol; 2023 Nov; 41(11):3195-3203. PubMed ID: 36811732
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Intravesical Chemohyperthermia vs. Bacillus Calmette-Guerin Instillation for Intermediate- and High-Risk Non-muscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis.
    Zhao H; Chan VW; Castellani D; Chan EO; Ong WLK; Peng Q; Moschini M; Krajewski W; Pradere B; Ng CF; Enikeev D; Vasdev N; Ekin G; Sousa A; Leon J; Guerrero-Ramos F; Tan WS; Kelly J; Shariat SF; Witjes JA; Teoh JY
    Front Surg; 2021; 8():775527. PubMed ID: 34888347
    [No Abstract]   [Full Text] [Related]  

  • 50. Adjuvant Intravesical Chemotherapy Versus Immunotherapy for All Risk Groups of Patients With Non-muscle Invasive Bladder Cancer.
    Djug H; Hasukic S; Jagodic S; Ivanic D
    Med Arch; 2023; 77(6):460-464. PubMed ID: 38313102
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prospective randomized trial of hexylaminolevulinate photodynamic-assisted transurethral resection of bladder tumour (TURBT) plus single-shot intravesical mitomycin C vs conventional white-light TURBT plus mitomycin C in newly presenting non-muscle-invasive bladder cancer.
    O'Brien T; Ray E; Chatterton K; Khan MS; Chandra A; Thomas K
    BJU Int; 2013 Dec; 112(8):1096-104. PubMed ID: 24053153
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Impact of systemic inflammatory markers on the response to Hyperthermic IntraVEsical Chemotherapy (HIVEC) in patients with non-muscle-invasive bladder cancer after bacillus Calmette-Guérin failure.
    Chiancone F; Fabiano M; Carrino M; Fedelini M; Meccariello C; Fedelini P
    Arab J Urol; 2021 Jan; 19(1):86-91. PubMed ID: 33763253
    [No Abstract]   [Full Text] [Related]  

  • 53. EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016.
    Babjuk M; Böhle A; Burger M; Capoun O; Cohen D; Compérat EM; Hernández V; Kaasinen E; Palou J; Rouprêt M; van Rhijn BWG; Shariat SF; Soukup V; Sylvester RJ; Zigeuner R
    Eur Urol; 2017 Mar; 71(3):447-461. PubMed ID: 27324428
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A randomized prospective study of intravesical prophylaxis in non-musle invasive bladder cancer at intermediate risk of recurrence: mitomycin chemotherapy vs BCG immunotherapy.
    Mangiarotti B; Trinchieri A; Del Nero A; Montanari E
    Arch Ital Urol Androl; 2008 Dec; 80(4):167-71. PubMed ID: 19235434
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Adverse events of hyperthermic intravesical chemotherapy for non-muscle invasive bladder cancer patients.
    Thomsen JA; Nielsen Dominiak H; Lindgren MS; Jensen JB
    Scand J Urol; 2021 Aug; 55(4):281-286. PubMed ID: 34124993
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Device-assisted intravesical chemotherapy versus bacillus Calmette-Guerin for intermediate or high-risk non-muscle invasive bladder cancer: a systematic reviewer and meta-analysis.
    You C; Li Q; Qing L; Li R; Wang Y; Cheng L; Dong Z
    Int Urol Nephrol; 2024 Jan; 56(1):103-120. PubMed ID: 37659995
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Hyperthermic intravesical chemotherapy with mitomycin-C for the treatment of high-risk non-muscle-invasive bladder cancer patients.
    Conroy S; Pang K; Jubber I; Hussain SA; Rosario DJ; Cumberbatch MG; Catto JWF; Noon AP
    BJUI Compass; 2023 May; 4(3):314-321. PubMed ID: 37025474
    [TBL] [Abstract][Full Text] [Related]  

  • 58. CALIBER: a phase II randomized feasibility trial of chemoablation with mitomycin-C vs surgical management in low-risk non-muscle-invasive bladder cancer.
    Mostafid AH; Porta N; Cresswell J; Griffiths TRL; Kelly JD; Penegar SR; Davenport K; McGrath JS; Campain N; Cooke P; Masood S; Knowles MA; Feber A; Knight A; Catto JWF; Lewis R; Hall E
    BJU Int; 2020 Jun; 125(6):817-826. PubMed ID: 32124514
    [TBL] [Abstract][Full Text] [Related]  

  • 59. HIVEC as an alternative option in non-muscle-invasive bladder cancer: Experiences from a high-volume center.
    Kastner L; Rieger C; Pfister D; Schmautz M; Storz E; Heidenreich A
    Urol Oncol; 2024 Aug; 42(8):245.e19-245.e26. PubMed ID: 38653592
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Long-term efficacy of hyperthermic intravesical chemotherapy for BCG-unresponsive non-muscle invasive bladder cancer.
    Pijpers OM; Hendricksen K; Mostafid H; de Jong FC; Rosier M; Mayor N; de Jong JJ; Boormans JL
    Urol Oncol; 2022 Feb; 40(2):62.e13-62.e20. PubMed ID: 34470725
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.